A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes

1. Garcia-Manero, G.
2. Khoury, H.J.
3. Jabbour, E.
4. Lancet, J.
5. Winski, S.L.
6. Cable, L.
7. Rush, S.
8. Maloney, L.
9. Hogeland, G.
10. Ptaszynski, M.
11. Calvo, M.C.
12. Bohannan, Z.
13. List, A.
14. Kantarjian, H.
15. Komrokji, R.